TFX Teleflex Incorporated

Teleflex to Present Innovative Interventional Access Technologies at the Annual Meeting and Postgraduate Course of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), to be Held in Barcelona, Spain on September 10-13, 2016

Teleflex Incorporated (NYSE: TFX) a leading global provider of medical devices for critical care, urology and surgery will showcase two of its advanced Arrow® Interventional Access Products at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Barcelona.

During the event, Teleflex will highlight both the Arrow® OnControl® Powered Bone Access System and the ARROW-Clark™ VectorFlow™ Chronic Hemodialysis Catheter, together with other technologically advanced products for interventional applications.

The Arrow® OnControl® Powered Bone Access System offers the ability to effectively1, safely and rapidly2 obtain high quality bone samples. Our bone lesion biopsy needle is designed specifically for multiple bone biopsies from a single cortical penetration. Using Teleflex’s patented handheld driver technology, the Arrow® OnControl® Powered Bone Access System provides interventional radiologists a fast reliable3 solution for accessing dense and hard-to-reach bone lesions.

The ARROW-Clark™ VectorFlow™ Catheter is the only catheter with an innovative tip designed to produce a helical, three-dimensional transition of blood entering and leaving the catheter.4 Designed for optimum performance, the ARROW-Clark™ VectorFlow™ Catheter (available in both retrograde and antegrade insertion platforms) is a tunneled hemodialysis catheter with symmetrical tip that is designed to reduce loss of lock solution (a contributing factor in reducing the risk of thrombus adherence), gives sustained high flows, minimizes recirculation and reduces the risk of platelet damage resulting from shear stress.5

During the CIRSE Congress on Sunday, September 11 and Monday, September 12, at 14:00 Prof. Dr. med. Roman Fischbach, Head of Radiology and Neuroradiology at Asklepios Klinik Altona, will lead in-booth sessions entitled "CT guided bone biopsy with the Arrow® OnControl® Powered Bone Access System. Clinical applications, technique and results."

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, ARROW-Clark, Deknatel, Hudson RCI, LMA, OnControl, Pilling, Rüsch, VectorFlow and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2016 Teleflex Incorporated. All rights reserved.

References:

1. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematology Reports 2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free article] [PubMed] verified March 2015.

2. Lee RK, Ng AW, Griffith JF. CT-guided bone biopsy with a battery-powered drill system: preliminary results. AJR Am J Roentgenol 2013;201(5):1093-5. doi:10.2214/AJR.12.10521. Available at: [PubMed] verified March 2015.

3. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematology Reports 2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free article] [PubMed] verified March 2015.

4. Clark T, et al. Computational Flow Dynamics and Preclinical Assessment of a Novel Hemodialysis Catheter. Seminars in Dialysis 2012;25(5):574-581. doi: 10.1111/j.1525-139X.2012.01052.*

5. Clark TWI, Isu G, Gallo D, Verdonck P, Morbiducci U. Comparison of symmetric hemodialysis catheters using computational fluid dynamics. Journal of Vascular and Interventional Radiology. 2015;26(2):252-259. doi: 10.1016/j.jvir.2014.11.004

EN
09/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcar...

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at . About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the ...

 PRESS RELEASE

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a...

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for pur...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Teleflex Inc: 5 directors

Five Directors at Teleflex Inc bought 5,500 shares at between 114.750USD and 115.860USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch